Biotech Startups

Nanostics is a precision health company developing non-invasive diagnostic tests and medical devices that use machine learning to detect and assess aggressive cancers such as prostate cancer, aiming to improve diagnosis and healthcare decisions. It serves clinicians and patients in the cancer diagnostics field.

2 investors

NanoVation Therapeutics develops lipid nanoparticle (LNP) and mRNA delivery technologies for gene therapies, supporting drug development partners across mRNA synthesis, LNP formulation, and preclinical delivery optimization. It works with pharmaceutical and biotech partners on end-to-end gene therapy delivery.

2 investors

Nanovery develops DNA-based nanorobotic sensors that quantify nucleic acid sequences, such as RNA therapeutics and biomarkers, in liquid samples using a standard plate reader. The platform serves biotechnology research and therapeutic analysis workflows.

2 investors

Napigen is a biotechnology company developing genome editing technology targeting the mitochondrial and chloroplast genomes.

2 investors

Natáur uses a synthetic biology platform that engineers microbes to produce naturally occurring compounds through fermentation, with its first product being bio-based taurine sold as a ready-to-use ingredient. The company applies metabolic engineering and fermentation to create sustainable bio-based nutrients for human and animal wellness.

2 investors

Native Traits recovers naturally occurring genetic traits from heritage crop varieties and incorporates them into hybrid seeds to improve yield, drought tolerance, and heat resilience. The company works with seed company partners to produce and market branded hybrids under the AgResilient line.

2 investors

Naturannova develops sustainable ingredients using science and technology, working to change how ingredients are produced. The company operates in the biotechnology space with a focus on sustainability.

2 investors

NatureMetrics provides a platform that unifies biodiversity data from multiple sources including eDNA, geospatial, and predictive analytics to help organizations monitor nature-related risks and report on environmental impact. The platform serves sustainability teams, ESG leaders, and risk officers who need to analyze biodiversity metrics and comply with environmental reporting standards like TNFD and CSRD.

2 investors

Ncardia develops induced pluripotent stem cell (iPSC) technologies and services for drug discovery, safety testing, and regenerative medicine applications. The company serves pharmaceutical and biotech organizations seeking advanced cellular models to accelerate therapeutic development and validate drug candidates.

2 investors

Nebuflow develops drug delivery technology for pharmaceutical applications. The company focuses on transforming how life-changing drugs are delivered.

2 investors

Nectin Therapeutics develops novel monoclonal antibodies and antibody-drug-conjugates to treat difficult-to-treat cancers by targeting immune evasion mechanisms. The company is a biotech firm with a pipeline focused on oncology immunotherapy, including its lead candidate NTX1088 currently in clinical trials.

2 investors

Nektar develops therapies that modulate the immune system to treat autoimmune diseases and inflammatory conditions, targeting the root causes of immune dysfunction. The company conducts research, therapeutic discovery, and clinical development, working with pharmaceutical partners to bring immune-mediated disease treatments to patients.

2 investors

NeoEarth develops performance improvements for industrial microalgae strains, combining microalgae biology research with cultivation and production process development. It works to scale industrial collaborations and partnerships around microalgae engineering.

2 investors

NeoBe Therapeutics develops engineered live biotherapeutics for oncology, combining synthetic biology and immunology to create next-generation cell therapies. The company serves cancer patients through collaborations with leading academic institutions and investors.

2 investors

NeoGenomics develops diagnostic tests and tools for cancer care, including tests for immunotherapy response monitoring, therapy selection, and minimal residual disease detection.

2 investors

2 investors

Neopathology develops tissue diagnostic assays and a proprietary platform called ONEPATHOLOGY that delivers rapid, accurate disease diagnosis and patient stratification for precision medicine treatments. The company combines spatial biology and deep-tissue profiling technologies to standardize tissue diagnostics.

2 investors

NervGen is a clinical-stage biotech company developing therapies for neurological conditions, with a focus on spinal cord injury and neurorepair. It maintains a drug pipeline and operates as a publicly traded company.

2 investors

NĒRx Biosciences develops small molecule inhibitors targeting DNA damage sensor proteins for cancer treatment, with initial focus on difficult-to-treat lung and ovarian cancers. The company builds on two decades of academic research from Indiana University's School of Medicine on DNA damage and repair mechanisms.

2 investors

Network Bio activates biobanks through securitization and capital infusion, providing research-grade data assets and operational infrastructure for precision medicine and biomedical research.

2 investors

Neural Dynamics Technologies develops neural interface technology aimed at advancing neuroscience research and treating neurological diseases. The company brings together neuroscientists, engineers, and clinicians in an interdisciplinary approach.

2 investors

Neuraptive is a biotechnology company staffed by professionals with expertise in research and development, manufacturing, and commercialization in the pharmaceutical industry.

2 investors

Neuraura Biotech develops proprietary 3D micro-electrode and microsensor technology for high-fidelity neural recording and percutaneous stimulation, used to improve diagnostic and therapeutic solutions for neurological, psychiatric and sensory conditions. The company commercializes technology transferred from the University of Calgary, with a stated focus on chronic, underserved health conditions including women's health.

2 investors

NeuraWorx is developing a wearable bioelectronic stimulator based on its Cerebrovascular Pacing System, intended for sale after clinical study and FDA clearance. The device is a neurostimulation medical technology in early development.

2 investors